In line with some of these considerations, a review of treatment sequencing of biologics for IBD suggested that patients with CD or UC should be treated with a non–anti-TNFα treatment, such as vedolizumab, prior to exposure to anti-TNFα treatment. This evidence concerns the gene TNF and inflammatory bowel disease.